Maridebart cafraglutide, an antibody-peptide conjugate, serves as a GLP-1 receptor agonist and a GIP receptor antagonist. It effectively reduces body weight and enhances metabolic markers in male obese mice and cynomolgus monkeys, showing promise for obesity research.